キャリアスクリーニングの世界市場：現状分析・予測 (2022年～2028年)

遺伝性疾患の有病率の上昇と、これらの疾患が子供に与える影響に関する意識の高まりが、キャリアスクリーニング市場の推進因子となっています。キャリアスクリーニングの市場規模は、体外受精・凍結保存の採用が増加していることから、約15％の安定した成長率が見込まれています。

当レポートでは、世界のキャリアスクリーニングの市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、法規制環境、需給動向、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法・前提因子

第3章 市場概要

第4章 エグゼクティブサマリー

第5章 COVID-19：キャリアスクリーニング市場への影響

第6章 キャリアスクリーニング市場：収益の推移・予測

第7章 市場洞察：タイプ別

• 拡張キャリアスクリーニング
• 標的疾患キャリアスクリーニング

第8章 市場洞察：疾患別

• 嚢胞性線維症
• テイ=サックス病
• ゴーシェ病
• 鎌状赤血球症
• 脊髄性筋萎縮症
• その他

第9章 市場洞察：技術別

• DNAシーケンシング
• ポリメラーゼ連鎖反応
• マイクロアレイ
• その他

第10章 市場洞察：エンドユーザー別

• 病院
• ラボ
• 診療所
• その他

第11章 市場洞察：地域別

• 北米
• 欧州
• アジア太平洋
• その他の地域

第12章 キャリアスクリーニング市場：市場力学

• 市場促進要因
• 市場課題
• 影響分析

第13章 キャリアスクリーニング市場：市場機会

第14章 キャリアスクリーニング市場：市場動向

第15章 需要サイド・供給サイドの分析

第16章 バリューチェーン分析

第17章 競合シナリオ

第18章 企業概要

• Myriad Genetics, Inc.
• Cepheid
• Illumina, Inc
• Thermo Fisher Scientific
• F. Hoffmann-La Roche Ltd
• Laboratory Corporation of America Holdings
• Otogenetics
• MedGenome
• Genentech, Inc
• CENTOGENE N.V.

第19章 免責事項

Carrier screening is a genetic test used to determine if a healthy person is a carrier of a recessive genetic disease. It provides life-lasting information about an individual's reproductive risk and their chances of having a child with a genetic disease. Genetic disorders are considered life-long disorders, these can be happened by mutation or by the inheritance of the defaulted genes from the family. The rising prevalence of genetic disorders and the rising awareness about the effect of these disorders on the child are the driving for the market of carrier screening. For instance, the World Health Organization estimates that 10 out of every 1000 people are affected. This means that between 70 million and 80 million people in the world are living with one of these diseases.

The Carrier Screening Market is expected to grow at a steady rate of around 15% owing to the increasing adoption of In-vitro fertilization and cryopreservation. Cryopreservation and in-vitro fertilization require the genetic screening of parents to understand the risk of the genetic disorder. For instance, as per the various research reports, each year, clinicians around the world perform more than 2.5 million IVF cycles.

Based on the type, the market has been categorized into expanded carrier screening and targeted disease carrier screening. Among them, the expanded carrier screening segment holds a dominant share of the market in 2021. The expanded carrier screening tests are the tests that cover the range of genetic disorder testing. These tests are performed to access the possibility of the highest occurring genetic diseases such as Tay-Sachs diseases. The companies are expanding their product launches in the category is an important factor responsible lucrative share of the segment in the market. For instance, in February 2020, Thermo Fisher Scientific Introduces NGS-Based Solution for Expanded Carrier Screening Research. The Ion Torrent CarrierSeq ECS Kit for the Ion GeneStudio S5 System consolidates a multi-platform approach to expanded carrier screening (ECS) into a single solution that extends the company's reproductive health research portfolio, which includes tools for prenatal, postnatal, invitro fertilization, and newborn screening analysis.

Based on the medical condition, the market has been categorized into cystic fibrosis, Tay Sachs, Gaucher disease, sickle cell disease, spinal muscular atrophy, and others. Among them, sickle cell disease held a considerable share in 2021. Sickle cell anemia is among the most common genetic disorders in which the red blood cells of the body change their shape from round to sickle cell and becomes rigid which makes them incompatible to carry enough oxygen. That results in anemia, loss of vision, weak immunity, and other conditions. The high prevalence of the disease in the weaker economies attributes to the significant share of the segment. For example, as per the World Health Organization, as high as 40 percent of people in some African countries have sickle cell trait.

Based on the technology, the market has been categorized into DNA sequencing, polymerase chain reaction, microarrays, and others. Among them, the DNA sequencing segment holds a prominent share of the market un 2021. This is mainly due to technological advancements in the technology, along with the expanding product categories and launches of products based on DNA sequencing attributes to the growth of the segment. For instance, in December 2022, Bio-Techne and Oxford Nanopore Technologies announced to codevelop sequencing assays for reproductive health and carrier screening.

Based on the end-users, the market has been categorized into hospitals, laboratories, clinics, and others. Among them, the laboratories segment held the dominant share in 2021. This is mainly due to the expertise of the laboratories in the diagnosis of various genetic disorders, increasing the patient pool in the labs for the diagnosis.

For a better understanding of the market adoption of the carrier screening industry, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America is anticipated hold a dominant market share in 2021. The presence of the major market players and increasing demand for the early detection of the genetic condition attributes to the dominating share of carrier screening in the region. Furthermore, increasing incidences of genetic and rare diseases are the contributing factors for the market growth in the region. For instance, according to the National Institutes of Health (NIH), there are approximately 7,000 rare diseases affecting between 25 and 30 million Americans.

Some of the major players operating in the market are Myriad Genetics, Inc.; Cepheid; Illumina, Inc; Thermo Fisher Scientific; F. Hoffmann-La Roche Ltd; Laboratory Corporation of America Holdings; Otogenetics; MedGenome; Genentech, Inc; and CENTOGENE N.V.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Carrier Screening Market
• 2.2. Research Methodology of the Carrier Screening Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE CARRIER SCREENING MARKET

6 CARRIER SCREENING MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY TYPE

• 7.1. Expanded Carrier Screening
• 7.2. Targeted Disease Carrier Screening

8 MARKET INSIGHTS BY MEDICAL CONDITION

• 8.1. Cystic Fibrosis
• 8.2. Tay-Sachs
• 8.3. Gaucher Disease
• 8.4. Sickle Cell Disease
• 8.5. Spinal Muscular Atrophy
• 8.6. Other

9 MARKET INSIGHTS BY TECHNOLOGY

• 9.1. DNA Sequencing
• 9.2. Polymerase Chain Reaction
• 9.3. Microarrays
• 9.4. Others

10 MARKET INSIGHTS BY END-USER

• 10.1. Hospitals
• 10.2. Laboratories
• 10.3. Clinics
• 10.4. Others

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. U.S.
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. U.K.
  • 11.2.3. France
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia-Pacific
  • 11.3.1. China
  • 11.3.2. Japan
  • 11.3.3. India
  • 11.3.4. Rest of Asia-Pacific
• 11.4. Rest of World

12 CARRIER SCREENING MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 CARRIER SCREENING MARKET OPPORTUNITIES

14 CARRIER SCREENING MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porters Fiver Forces Analysis

18 COMPANY PROFILED

• 18.1. Myriad Genetics, Inc.
• 18.2. Cepheid
• 18.3. Illumina, Inc
• 18.4. Thermo Fisher Scientific
• 18.5. F. Hoffmann-La Roche Ltd
• 18.6. Laboratory Corporation of America Holdings
• 18.7. Otogenetics
• 18.8. MedGenome
• 18.9. Genentech, Inc
• 18.10. CENTOGENE N.V.

19 DISCLAIMER